|
Published by: BCC Research
Published: Apr. 1, 2003 - 287 Pages
Table of Contents
Introduction
Study Goals And Objectives
Reasons For Doing The Study
Scope And Format
Methodology
Analyst Credentials
Related Bcc Studies
Summary
Summary Table:
Total U.S. Market For Drugs For The Elderly, Through 2007 ($ Billions, %)
Summary Figure:
Total U.S. Market For Drugs For The Elderly, 2000-2007 ($ Billions)
Industry Overview
Theories Of Aging
Biological Theories
Causal Theories
Psychological Theories
Aging In Various Cultures
Age-Related Changes In The Elderly
Cardiovascular System
Cardiovascular System (Continued)
Endocrine System
Female Reproductive System
Gastrointestinal System And Nutrition
Gastrointestinal System And Nutrition (Continued)
Integumentary System
Musculoskeletal System
Neurological System
Pulmonary System
Renal And Urinary System
Diseases And Conditions Affecting The Elderly Population
Table 1 Most Common Illnesses In The Older Age Group
History And Growth Of The Elderly Drug Market
Table 2 Prescription Drug Use By Age Group
Table 3 Average Annual Prescription Drug Expenditures, By Age Group ($)
Drug Therapy In The Elderly
Pharmacokinetic Changes
Absorption
Distribution
Metabolism
Excretion
Rational Drug Therapy
Polypharmacy
Adverse Drug Reactions
Table 4 Commonly Observed Adverse Drug Reactions In The Elderly
Noncompliance
Medication Management
Demographics, Incidence, Mortality
Aging In America
Table 5 U.S. Population Estimates And Projections, By Age Group, For Specific Years, 1900 To 2050 (Thousands)
Figure 1 U.S. Population Estimates And Projections, By Age Group, For Specific Years, 1900-2050
Table 6 Estimated U.S. Population, By Age Group, Through 2007 (Thousands)
Gender And Age
Table 7 Estiamtes Of Expected U.S. Life Expectancy At Birth And Projections, By Sex, 2000, 2005 And 2010 (Years)
U.S. Geographic Distribution
Table 8 Estimated U.S. Elderly (Age 65 And Up) Population, By U.S. State, 2000 And 2025 (Thousands)
Table 8 (Continued)
Marital Status
Table 9 Marital Status Of The 65 And Over Age Population By Sex, 2001 (Thousands)
Economic Status
Table 10 Household Income By Selected Age Group, 2001 ($ Thousands)
Table 11 Poverty Level Of Persons 65 Years And Over By Selected Characteristic, 1999 (Thousands, %)
Health Care
Table 12 Deaths Of 65 And Over Population, By Race And Leading Cause, 1998
Table 13 Percent Distribution Of Number Of Visits To Health Care Professionals By Selected Age Group, 1998
Table 14 Hospital Discharges And Days Of Care By Elderly Age Group, 1999 (# Thousands)
Long-Term Care
Table 15 Population 65 Years And Over By Age For Nursing Homes, Home Health, Or Hospice Care, Estimated 2000
Trends Affecting The Market
Public Policy Development
Insurance Issues, Medicare, Managed Care, Health Care Funding
Social, Legal, And Ethical Issues
Table 16 Selected Racial Origins Of 65 Year And Over U.S. Population, 2000 (Thousands, %)
Mass Media Attitude
Political Involvement
Generic Drugs
Generic Drugs (Continued)
The Aging Network
The Aging Network (Continued)
Market Analysis
Anti-Infective Agents
Overview
Product Description
Product Description (Continued)
Product Description (Continued)
Table 17 Selected U.S. Anti-Infective Agent Comparison, Drugs Commonly Used By The Elderly
Table 17 (Continued)
Table 17 (Continued)
Research And Development
Table 18 U.S. Elderly Anti-Infective Agents Under Development, By Developer And Development Phase
Market Size And Growth
Total Market
Table 19 Total U.S. Anti-Infective Agent Market By Percent Usage And Revenues For Over And Under Age 65, Through 2007 ($ Billions)
Figure 2 Total U.S. Anti-Infective Agent Market By Percent Usage And Revenues For Over And Under Age 65, 2002 And 2007 ($ Billions, %)
Table 20 U.S. Elderly Anti-Infective Agent Market By Product Sub-Type, Through 2007 ($ Millions)
Figure 3 U.S. Elderly Anti-Infective Agent Market By Product Sub-Type, 2000-2007 ($ Millions)
Market Percent Distribution By Product Sub-Type
Table 21 U.S. Elderly Anti-Infective Agent Market Percent Distribution By Product Sub-Type, Through 2007 (%)
Figure 4 U.S. Elderly Anti-Infective Agent Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Competitive Structure And Market Share
Competitive Structure And Market Share (Continued)
Table 22 U.S. Elderly Anti-Infective Agents Market, Competitive Market Share, 2002 ($ Millions)
Figure 5 U.S. Elderly Anti-Infective Agents Market, Competitive Market Share By Revenues, 2002
Cardiovascular Drugs And Blood Modifiers
Overview
Table 23 Common Causes Of Congestive Heart Failure
Incidence And Prevalence
Advances In Prevention And Treatment
Advances In Prevention And Treatment (Continued)
Hypercholesterolemia
Hypertension
Product Description
Product Description (Continued)
Table 24 Selected U.S. Cardiovascular Drug And Blood Modifiers Comparison, Drugs Commonly Used By The Eldelry
Table 24 (Continued)
Table 24 (Continued)
Research And Development
Table 25 U.S. Elderly Cardiovascular Drugs And Blood Modifiers Under Development, By Developer And Development Phase
Table 25 (Continued)
Market Size And Growth
Total Market
Table 26 Total U.S. Cardiovascular Drug And Blood Modifier Market By Percent Usage And Revenues For Over And Under Age 65, Through 2007 ($ Billions)
Figure 6 Total U.S. Cardiovascular Drug And Blood Modifier Market By Percent Usage And Revenues For Over And Under Age 65, 2002 And 2007 ($ Billions, %)
Total Market (Continued)
Table 27 U.S. Elderly Cardiovascular Drugs And Blood Modifiers Market By Product Sub-Type, Through 2007 ($ Millions)
Figure 7 U.S. Elderly Cardiovascular Drugs And Blood Modifiers Markets By Product Sub-Type, 2000-2007 ($ Millions)
Market Percent Distribution By Product Sub-Type
Table 28 U.S. Elderly Cardiovascular Drugs And Blood Modifiers Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Figure 8 U.S. Elderly Cardiovascular Drugs And Blood Modifiers Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Competitive Structure And Market Share
Table 29 U.S. Elderly Cardiovasulcar Drugs And Blood Modifiers Market, Competitive Market Share, 2002 ($ Millions)
Figure 9 U.S. Elderly Cardiovascular Drugs And Blood Modifiers Market, Competitive Market Share By Revenues, 2002 (%)
Central Nervous System Drugs
Overview
Alzheimer's Disease
Anxiety
Cerebrovascular Disease
Dementia
Depression
Table 30 Drugs That May Precipitate Depression
Epilepsy
Osteoarthritis
Osteoarthritis (Continued)
Osteoarthritis (Continued)
Parkinson's Disease
Rheumatoid Arthritis
Table 31 Selected U.S. Central Nervous System Drug Comparison, Drugs Commonly Used By The Elderly
Table 31 (Continued)
Table 31 (Continued)
Table 31 (Continued)
Research And Development
Table 32 U.S. Elderly Central Nervous System Drugs Under Development, By Developer And Development Phase
Table 32 (Continued)
Market Size And Growth
Total Market
Table 33 Total U.S. Central Nervous System Drug Market By Percent Usage And Revenues For Over And Under Age 65, Through 2007 ($ Billions)
Figure 10 Total U.S. Central Nervous System Drug Market By Percent Usage And Revenues For Over And Under Age 65, 2002 And 2007 ($ Billions, %)
Table 34 U.S. Elderly Central Nervous System Drugs Market By Product Sub-Type, Through 2007 ($ Millions)
Figure 11 U.S. Elderly Central Nervous System Drugs Markets By Product Sub-Type, 2000-2007 ($ Millions)
Market Percent Distribution By Product Sub-Type
Table 35 U.S. Elderly Central Nervous System Drugs Market Percent Distribution By Product Sub-Type, Through 2007 (%)
Figure 12 U.S. Elderly Central Nervous System Drugs Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Competitive Structure And Market Share
Competitive Structure And Market Share (Continued)
Table 36 U.S. Elderly Central Nervous System Drugs Market, Competitive Market Share By Revenues, 2002 ($ Millions)
Figure 13 U.S. Elderly Central Nervous System Drugs Market, Competitive Market Share By Revenues, 2002 (%)
Dermatologic And Sensory Organ Drugs
Overview
Product Description
Product Description (Continued)
Table 37 Selected U.S. Dermatologic And Sensory Organ Drug Comparison, Drugs Commonly Used By The Elderly
Table 37 (Continued)
Table 37 (Continued)
Research And Development
Table 38 U.S. Elderly Dermatologic And Sensory Organ Drugs Under Development, By Developer And Development Phase
Table 38 (Continued)
Market Size And Growth
Total Market
Table 39 Total U.S. Dermatologic And Sensory Organ Drug Market By Percent Usage And Revenues For Over And Under Age 65, Through 2007 ($ Billions)
Figure 14 Total U.S. Dermatologic And Sensory Organ Drug Market By Percent Usage And Revenues For Over And Under Age 65, 2002 And 2007 ($ Billions, %)
Table 40 U.S. Elderly Dermatologic And Sensory Organ Drug Market By Product Sub-Type, Through 2007 ($ Millions)
Figure 15 U.S. Elderly Dermatologic And Sensory Organ Drug Markets By Product Sub-Type, 2000-2007 ($ Millions)
Market Percent Distribution By Product Sub-Type
Table 41 U.S. Elderly Dermatologic And Sensory Organ Drug Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Figure 16 U.S. Elderly Dermatologic And Sensory Organ Drug Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Competitive Structure And Market Share
Table 42 U.S. Elderly Dermatologic And Sensory Organ Drug Market, Competitive Market Share By Revenues, 2002 ($ Millions)
Figure 17 U.S. Elderly Dermatologic And Sensory Organ Drug Market, Competitive Market Share By Revenues, 2002
Gastrointestinal Drugs
Overview
Product Description
Product Description (Continued)
Product Description (Continued)
Table 43 Selected U.S. Gastrointestinal Drug Comparison, Drugs Commonly Used By The Elderly
Research And Development
Table 44 U.S. Elderly Gastrointestinal Drugs Under Development, By Developer And Development Phase
Market Size And Growth
Total Market
Table 45 Total U.S. Gastrointestinal Drug Market By Percent Usage And Revenues For Over And Under Age 65, Through 2007 ($ Billions)
Figure 18 Total U.S. Gastrointestinal Drug Market By Percent Usage And Revenues For Over And Under Age 65, 2002-2007 ($ Billions, %)
Table 46 U.S. Elderly Gastrointestinal Drugs Market By Product Sub-Type, Through 2007 ($ Millions)
Figure 19 U.S. Elderly Gastrointestinal Drugs Markets By Product Sub-Type, 2000-2007 ($ Millions)
Market Percent Distribution By Product Sub-Type
Table 47 U.S. Elderly Gastrointestinal Drugs Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Figure 20 U.S. Elderly Gastrointestinal Drugs Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Competitive Structure And Market Share
Table 48 U.S. Elderly Gastrointestinal Drugs Market, Competitive Market Share By Revenues, 2002 ($ Millions)
Table 48 (Continued)
Figure 21 U.S. Elderly Gastrointestinal Drugs Market, Competitive Market Share By Revenues, 2002 ($ Millions)
Kidney And Urinary System Drugs
Overview
Product Description
Table 49 Selected U.S. Kidney And Urinary System Drug Comparison, Drugs Commonly Used By The Elderly
Research And Development
Table 50 U.S. Elderly Kidney And Urinary System Drugs Under Development, By Developer And Development Phase
Market Size And Growth
Total Market
Table 51 Total U.S. Kidney And Urinary System Drug Market By Percent Usage And Revenues For Over And Under Age 65, Through 2007 ($ Billions)
Figure 22 Total U.S. Kidney And Urinary System Drug Market By Percent Usage And Revenues For Over And Under Age 65, 2002 And 2007 ($ Billions)
Table 52 U.S. Elderly Kidney And Urinary System Drugs Market By Product Sub-Type, Through 2007 ($ Millions)
Figure 23 U.S. Elderly Kidney And Urinary System Drugs Markets By Product Sub-Type, 2000-2007 ($ Millions)
Market Percent Distribution By Product Sub-Type
Table 53 U.S. Elderly Kidney And Urinary System Drugs Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Figure 24 U.S. Elderly Kidney And Urinary System Drugs Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Competitive Structure And Market Share
Table 54 U.S. Elderly Kidney And Urinary System Drugs Market, Competitive Market Share By Revenues, 2002 ($ Millions)
Figure 25 U.S. Elderly Kidney And Urinary System Drugs Market, Competitive Market Share By Revenues, 2002 (%)
Malignant And Immune Disease Drugs
Overview
Product Description
Product Description (Continued)
Product Description (Continued)
Product Description (Continued)
Product Description (Continued)
Table 55 Selected U.S. Malignant And Immune Disease Drugs, Drugs Commonly Used By The Elderly
Research And Development
Table 56 U.S. Elderly Malignant And Immune Disease Drugs Under Development, By Developer And Development Phase
Market Size And Growth
Total Market
Table 57 Total U.S. Malignant And Immune Disease Drug Market By Percent Usage And Revenues For Over And Under Age 65, Through 2007 ($ Billions)
Figure 26 Total U.S. Malignant And Immune Disease Drug Market By Percent Usage And Revenues For Over And Under Age 65, 2002 And 2007 ($ Billions, %)
Table 58 U.S. Elderly Malignant And Immune Disease Drugs Market By Product Sub-Type, Through 2007 ($ Millions)
Figure 27 U.S. Elderly Malignant And Immune Disease Drugs Markets By Product Sub-Type, 2000-2007 ($ Millions)
Competitive Structure And Market Share
Table 59 U.S. Elderly Malignant And Immune Disease Drugs Market, Competitive Market Share By Revenues, 2002 ($ Millions)
Figure 28 U.S. Elderly Malignant And Immune Disease Drugs Market, Competitive Market Share By Revenues, 2002 ($ Millions)
Metabolic, Endocrine And Hormone Drugs
Overview
Osteoporosis
Diabetes
Thyroid Disorders
Product Description
Product Description (Continued)
Table 60 Selected U.S. Metabolic, Endocrine, And Hormone Drug Comparison, Drugs Commonly Used By The Elderly
Research And Development
Table 61 U.S. Elderly Metabolic, Endocrine, And Hormone Drugs Under Development, By Developer And Development Phase
Market Size And Growth
Total Market
Table 62 Total U.S. Metabolic, Endocrine, And Hormone Drug Market By Percent Usage And Revenues For Over And Under Age 65, Through 2007 ($ Billions)
Figure 29 Total U.S. Metabolic, Endocrine, And Hormone Drug Market By Percent Usage And Revenues For Over And Under Age 65, 2002 And 2007 ($ Billions, %)
Table 63 U.S. Elderly Metabolic, Endocrine And Hormone Drugs Market By Product Sub-Type, Through 2007 ($ Millions)
Figure 30 U.S. Elderly Metabolic, Endocrine And Hormone Drugs Markets By Product Sub-Type, 2000-2007 ($ Millions)
Market Percent Distribution By Product Sub-Type
Table 64 U.S. Elderly Metabolic, Endocrine And Hormone Drugs Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Figure 31 U.S. Elderly Metabolic, Endocrine And Hormone Drugs Market Percent Distribution By Product Sub-Type, 2000-2007
Competitive Structure And Market Share
Table 65 U.S. Elderly Metabolic, Endocrine, And Hormone Drugs Market, Competitive Market Share By Revenues, 2002 ($ Millions)
Figure 32 U.S. Elderly Metabolic, Endocrine, And Hormone Drugs Market, Competitive Market Share By Revenues, 2002 (%)
Respiratory Drugs
Overview
Product Description
Product Description (Continued)
Table 66 Selected U.S. Respiratory Drug Comparison, Drugs Commonly Used By The Elderly
Research And Development
Table 67 U.S. Elderly Respiratory Drugs Under Development, By Developer And Development Phase
Market Size And Growth
Total Market
Table 68 Total U.S. Respiratory Drug Market By Percent Usage And Revenues For Over And Under Age 65, Through 2007 ($ Billions)
Figure 33 Total U.S. Respiratory Drug Market By Percent Usage And Revenues For Over And Under Age 65, 2002 And 2007 ($ Billions, %)
Total Market (Continued)
Table 69 U.S. Elderly Respiratory Drugs Market By Product Sub-Type, Through 2007 ($ Millions)
Figure 34 U.S. Elderly Respiratory Drugs Markets By Product Sub-Type, 2000-2007 ($ Millions)
Market Percent Distribution By Product Sub-Type
Table 70 U.S. Elderly Respiratory Drugs Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Figure 35 U.S. Elderly Respiratory Drugs Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Competitive Structure And Market Share
Table 71 U.S. Elderly Respiratory Drugs Market, Competitive Market Share By Revenues, 2002 ($ Millions)
Figure 36 U.S. Elderly Respiratory Drugs Market, Competitive Market Share By Revenues, 2002 ($ Millions)
Sexual Dysfunction And Genital Organ Drugs
Overview
Product Description
Table 72 Selected U.S. Sexual Dysfunction And Genital Organ Drug Comparison, Drugs Commonly Used By The Elderly
Research And Development
Table 73 U.S. Elderly Sexual Dysfunction And Genital Organ Drugs Under Development, By Developer And Development Phase
Market Size And Growth
Total Market
Table 74 Total U.S. Sexual Dysfunction And Genital Organ Market By Percent Usage And Revenues For Over And Under Age 65, Through 2007 ($ Billions)
Figure 37 Total U.S. Sexual Dysfunction And Genital Organ Drug Market By Percent Usage And Revenues For Over And Under Age 65, 2002 And 2007 ($ Billions, %)
Table 75 U.S. Elderly Sexual Dysfunction And Genital Organ Drugs Market By Product Sub-Type, Through 2007 ($ Millions)
Figure 38 U.S. Elderly Sexual Dysfunction And Genital Organ Drugs Markets By Product Sub-Type, 2000-2007 ($ Millions)
Market Percent Distribution By Product Sub-Type
Table 76 U.S. Elderly Sexual Dysfunction And Genital Organ Drugs Market Percent Distribution By Product Sub-Type, 2000-2007 (%)
Figure 39 U.S. Elderly Sexual Dysfunction And Genital Organ Drugs Market Percent Distribution By Product Sub-Type, 2002 And 2007 (%)
Competitive Structure And Market Share
Table 77 U.S. Elderly Sexual Dysfunction And Genital Organ Drugs Market, Competitive Market Share By Revenues, 2002 ($ Millions)
Figure 40 U.S. Elderly Sexual Dysfunction And Genital Organ Drugs Market, Competitive Market Share By Revenues, 2002 (%)
Market Summary
Total U.S. Market For Drugs For The Elderly
Table 78 Total U.S. Market For Drugs For The Elderly By Segment, Through 2007 ($ Millions)
Figure 41 Total U.S. Market For Drugs For The Elderly By Segment, 2002 And 2007
Table 79 Total U.S. Market For Drugs For The Elderly, Through 2007 ($ Billions)
Figure 42 Total U.S. Market For Drugs For The Elderly, 2002 And 2007 (%)
Technology
Current Uses Of Technology
Drug Patent Evaluation
Drug Patent Evaluation (Continued)
Table 80 U.S. Patent And Exclusivity Information By Drug* For Commonly Used Drugs In The Elderly
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Table 80 (Continued)
Technology Patent Evaluation
Table 81 Examples Of Technology Patents Benefiting The U.S. Elderly Population, By Number And Company
Industry Participants And Competitive Analysis
Table 82 Industry Participants By Product Type
Table 82 (Continued)
Table 82 (Continued)
Figure 43 Industry Participation By Number Of Segments With Product Participation
Figure 44 Distribution Of Industry Participants By Product Segment Participation (%)
Figure 44 (Continued)
Table 83 Approved Drugs Used For The Elderly By Manufacturer
Table 83 (Continued)
Table 83 (Continued)
Table 83 (Continued)
Company Profiles
Abbott Laboratories, Inc.
Alcon Laboratories, Inc.
Allergan, Inc.
Alza Corp.
Amgen, Inc.
Astrazeneca Plc
Aventis Pharmaceuticals, Inc.
Bausch & Lomb, Inc.
Bayer Corp.
Boehringer Ingelheim Gmbh (Roxane Laboratories, Inc.)
Roxane Laboratories, Inc.
Bristol-Myers Squibb Company (Apothecon, Inc., Bristol-Myers Squibb Oncology, Westwood Squibb)
Apothecon, Inc.
Bristol-Myers Squibb Oncology
Westwood Squibb
Eli Lilly & Company
Forest Laboratories, Inc.
Glaxosmithkline Plc
Johnson & Johnson (Janssen Pharmaceutica, Ortho-Mcneil Pharmaceuticals, Ortho Biotech Products)
Janssen Pharmaceutica Products, L.P.
Ortho-Mcneil Pharmaceuticals, Inc.
Ortho Biotech Products, L.P.
Merck & Co., Inc.
Novartis Pharmaceuticals Corp. (Novartis Ophthalmics, Inc.)
Novartis Ophthalmics, Inc.
Par Pharmaceutical, Inc.
Pfizer, Inc.
Agouron Pharmaceuticals, Inc.
Pharmacia Corporation
Roche Group (Hoffmann-Laroche, Inc.)
Hoffmann-Laroche, Inc.
Schering-Plough Corporation
Tap Pharmaceutical Products, Inc.
Wyeth
Appendices
Figure 45 Companies Mentioned In The Market For Drugs For The Elderly
Figure 45 (Continued)
Appendix I: Contact Information For Leading Drug Manufacturers
Abbott Laboratories
Akorn, Inc.
Alcon Laboratories, Inc.
Allergan, Inc.
Alza Corp.
Amarin Pharmaceuticals, Inc.
Amgen, Inc.
Apothecon, Inc.
Astrazeneca Plc
Astrazeneca Pharmaceuticals Lp
Athena Diagnostics
Aventis Pharmaceuticals, Inc.
Basf Corp.
Bausch & Lomb, Inc.
Barr Laboratories, Inc.
Baxter Healthcare Corp.
Bayer Corp.
Bedford Laboratories
Biovail Pharmaceuticals, Inc. (Previously Dj Pharma)
Bristol-Myers Squibb Oncology
Bristol-Myers Squibb Co.
Celltech Group Plc
Duramed
Elan Pharmaceuticals, Inc.
Eli Lilly & Co.
Endo Pharmaceuticals, Inc.
First Horizon Pharmaceutical Corp.
Fleming & Co.
Forest Laboratories, Inc.
Fujisawa Pharmaceutical Co., Ltd.
Genetech, Inc.
Gilead Sciences, Inc.
Glaxosmithkline Plc
Hoffmann-La Roche, Inc.
Icn Pharmaceuticals, Inc.
Immunex Corp.
Janssen Pharmaceutica Products, L.P
Johnson & Johnson
Johnson & Johnson
Jones Pharma, Inc.
King Pharmaceuticals, Inc.
Knoll Laboratories
Abbott Laboratories
Liposome Co., The
Elan Corp., Plc
Merck & Co., Inc.
Monarch Pharmaceuticals
Mylan Laboratories, Inc.
Novartis Pharmaceuticals Corp.
Novartis Ophthalmics, Inc.
Novartis Pharmaceuticals Corp.
Novo Nordisk A/S
Novo Allé
Novo Nordisk Pharmaceuticals, Inc.
Oclassen Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc.
Ortho-Mcneil Pharmaceutical, Inc.
Johnson & Johnson
Ortho Biotech Products, L.P.
Johnson & Johnson
Par Pharmaceutical, Inc.
Pharmaceutical Resources, Inc.
Pfizer, Inc.
Pharmacia Corp.
Purdue Pharma L.P.
Procter & Gamble Co., The
Roxane Laboratories, Inc.
Salix Pharmaceuticals, Ltd.
Sankyo Pharma, Inc.
Sanofi-Synthelabo
Savage Laboratories
Schering-Plough Corp.
Schwarz Pharma, Inc.
Sigma-Tau, Inc.
Solvay Pharmaceuticals, Inc.
Somerset Pharmaceuticals, Inc.
Tap Pharmaceutical Products, Inc.
Ucb Pharma
Unimed Pharmaceuticals, Inc.
Solvay Pharmaceuticals, Inc.
Upsher-Smith Laboratories
Wallace Pharmaceuticals
Warner-Chilcott, Plc
Warner-Lambert
Pfizer, Inc.
Wellspring Pharmaceutical Corp.
Westwood-Squibb
Bristol-Myers Squibb Co.
Women First Healthcare, Inc.
Wyeth
Appendix Ii: Other Manufacturers And Companies
3m Pharmaceuticals
3m Co.
Aaipharma, Inc.
Abbott Hospital Products
Abbott Laboratories
Actelion Pharmaceuticals U.S., Inc.
Adolor Corp.
Aeropharm Technology, Inc.
Afferon Corp.
Alexion Pharmaceuticals, Inc.
Allos Therapeutics, Inc.
Amylin Pharmaceuticals, Inc.
Antex Biologics
Antigenics, Inc.
Apotex Corp.
Aradigm Corp.
Artecel Sciences, Inc.
Atrix Laboratories
Auxilium Pharmaceuticals, Inc.
Aventis Pharma
Aventis
Avi Biopharma
Axcan Pharma, Inc.
Axonyx, Inc.
Barr Laboratories, Inc.
Bayer Ag
Berlex Laboratories, Inc.
Bionumerik Pharmaceuticals, Inc.
Boehringer Ingelheim Gmbh
Bone Care International, Inc.
Boston Life Sciences, Inc.
Centocor, Inc.
Cephalon, Inc.
Collateral Therapeutics, Inc.
Corixa Corp.
Cortex Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc.
Curacyte Ag
Cv Therapeutics, Inc.
Depomed, Inc.
Diacrin, Inc.
Dimethaid Research, Inc.
Discovery Laboratories, Inc.
Dr. Reddy's Laboratories, Inc.
E.I. Dupont De Nemours & Co.
Eisai Co., Ltd.
Endovasc Ltd., Inc.
Faro Pharmaceuticals
First Horizon Pharmaceutical Corp.
G & W Laboratories, Inc.
Genesis Research & Development Corp., Ltd.
Geneva Pharmaceuticals, Inc.
Genome Therapeutics Corp.
Genzyme Corp.
Guilford Pharmaceuticals, Inc.
Hermes Biosciences, Inc.
Human Genome Sciences, Inc.
Icos Corp.
Idec Pharmaceuticals Corp.
Impax Laboratories, Inc.
Inhale Therapeutic System, Inc.
Inkine Pharmaceutical Co., Inc.
Imclone Systems, Inc.
Insite Vision, Inc.
Insmed, Inc.
Indevus Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
Ivax Corp.
Kyorin Pharmaceutical Co., Ltd.
Lg Chem, Ltd.
Ligand Pharmaceuticals, Inc.
Lion Bioscience, Inc.
Macrochem Corp.
Mcneil Consumer Healthcare
Medarex, Inc.
Medicines Co., The
Medigene Ag
Metabolex, Inc.
Milkhaus Laboratory, Inc.
Miravant Medical Technologies
Monsanto Co.
Myogen, Inc.
Nastech Pharmaceutical Co., Inc.
Neurobiological Technologies, Inc.
Neurocrine Biosciences, Inc.
Neurogen Corp.
Nexmed, Inc.
Nitromed, Inc.
Northwest Biotherapeutics
Noven Pharmaceuticals, Inc.
Nps Pharmaceuticals, Inc.
Organon, Inc.
Orion Pharma
Palatin Technologies, Inc.
Pharmaceutical Resources, Inc.
Pharmacyclics, Inc.
Polymedica Corp.
Praecis Pharmaceuticals, Inc.
Profile Therapeutics Plc
Prometheus Laboratories, Inc.
Protein Design Labs, Inc.
Qlt, Inc.
Roche Group
Schering Ag
Scios, Inc.
Sepracor, Inc.
Serono Laboratories, Inc.
Sheffield Pharmaceuticals, Inc.
Shire Pharmaceuticals Group Plc
Spectrum Pharmaceutical
Supergen Corp.
Syn X Pharma, Inc.
Synsorb Biotech, Inc.
Takeda Chemical Industries, Ltd.
Teva Pharmaceuticals Usa
Titan Pharmaceuticals, Inc.
United Therapeutics Corp.
Vasogen, Inc.
Vical, Inc.
Viropharma, Inc.
Vivus, Inc.
Watson Pharmaceuticals, Inc
Zonagen, Inc.
Appendix Iii: Association, Organizations, And Universities
American Association Of Retired Persons
Baylor University
Center On An Aging Society
Federal Trade Commision (Ftc)
Food And Drug Administration (Fda)
Gerontology Research Center
Institute For Diabetes Discovery, The
National Council On The Aging, The (Ncoa)
National Institute On Aging (Nia)
National Institutes Of Health
University Of Oklahoma
University Of South Florida
University Of Texas At Austin
University Of Toronto
U.S. Department Of Health & Human Services, The
U.S. Patent And Trademark Office
AbstractThis study will provide the reader with an overall analysis of drugs available in the United States used for elderly populations, men and women 65 and over. Included in this report is a description of products in various therapeutic areas, which are vital for the health and quality of life for the elderly. Major therapeutic areas include bone metabolism regulators, cardiovascular drugs and blood modifiers, central nervous system agents, respiratory drugs and several others. Issues and trends affecting the health of the elderly are discussed in-depth including such areas as: demographics of population; incidence and mortality; social, legal and ethical issues; insurance issues, including Medicare and Medicaid; quality of life and therapeutic objectives for the elderly; the impact of generic drugs and several other issues. Each therapeutic segment includes detailed market data including revenues for 2000, 2001, 2002 and 2007; AAGR data for 2002 to 2007; competitive market share data and more.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
